EI1 is a potent and selective small molecule inhibitor of EZH2, demonstrating IC50 values of 15 nM against wild-type and 13 nM against the Y641F mutant. It is widely used in vitro and in vivo to study epigenetic mechanisms in oncology, particularly for cancers driven by EZH2 dysregulation such as lymphomas.